Disease-Dependent Changes in Target Abundance

Why Disease-Dependent Target Abundance Matters

A disease state can change how much of an antibody’s target is present, even when the antibody’s binding properties are unchanged. More target can create a larger binding sink, alter how much antibody remains free, and change the amount of drug–target complex. The direction and size of these effects depend on the dosing conditions, target turnover, and whether complex formation leads to internalization.

The earlier material on target turnover and free versus total target distinguishes free target from target bound in complex. Here the focus is on representing a disease-related change in target synthesis or loss and tracing its consequences through a TMDD model. A useful starting point is to let disease alter a parameter of the target balance, rather than applying an unexplained multiplier to antibody concentration or clearance.

Adding Disease Effects to the TMDD Model

Let \(D\) be free antibody concentration, \(R\) free target concentration, and \(C\) drug–target complex concentration. In a one-compartment model with one-to-one binding, a standard mass-balance form is:

Here \(u(t)\) is the antibody input rate expressed as a concentration per time, \(k_{\mathrm{el}}\) is the first-order elimination rate of free antibody, \(k_{\mathrm{on}}\) and \(k_{\mathrm{off}}\) are association and dissociation rate constants, and \(k_{\mathrm{int}}\) is the rate at which complex is internalized. The equations assume well-mixed concentrations, one-to-one binding, and the stated first-order loss processes. They do not include spatial target distribution or additional binding partners.

A disease state \(z\) can be represented by changing target synthesis, degradation, or both. For example, a synthesis multiplier \(q(z)\) gives \(k_{\mathrm{syn}}(z)=q(z)k_{\mathrm{syn,ref}}\). If degradation is unchanged, the drug-free steady-state abundance is multiplied by \(q(z)\). Alternatively, changing \(k_{\mathrm{deg}}(z)\) changes both the steady-state abundance and the speed of turnover. In general:

This calculation describes the drug-free steady state. During treatment, binding and complex internalization also affect target balance. Summing the free-target and complex equations gives:

Thus, the target total \(R+C\) is not generally fixed during treatment. It changes through synthesis, degradation of free target, and internalization of complex. A disease multiplier applied to a drug-free baseline is not automatically an exact description of on-treatment target abundance.

From Target Abundance to Antibody Exposure and Occupancy

The direction of a target-abundance effect is easiest to see under a stated approximation. Suppose binding is fast relative to the timescale of interest, the accessible total target pool \(R_{\mathrm{tot}}\) is approximately buffered, and complex is described by the quasi-steady-state relation \(C=R_{\mathrm{tot}}D/(K_{\mathrm{ss}}+D)\), where \(K_{\mathrm{ss}}=(k_{\mathrm{off}}+k_{\mathrm{int}})/k_{\mathrm{on}}\). This is a reduced description, not a replacement for the full differential equations when target depletion or turnover is important. The corresponding occupied fraction is:

At a fixed free antibody concentration, this approximation gives the same fractional occupancy regardless of target abundance, but a larger target pool produces more complex. In an actual PK model, free antibody need not remain fixed. A larger target pool can bind more antibody and, when complex is internalized, can increase target-mediated antibody loss. The resulting reduction in free antibody can in turn reduce fractional occupancy. These are conditional predictions: the full model and dosing conditions determine the net change.

A short derivation makes the distinction clear. If the accessible pool is treated as fixed and \(C=R_{\mathrm{tot}}D/(K_{\mathrm{ss}}+D)\), then increasing \(R_{\mathrm{tot}}\) at fixed \(D\) scales \(C\) upward but cancels from the fraction \(C/R_{\mathrm{tot}}\). If instead a fixed total antibody concentration \(D_{\mathrm{tot}}=D+C\) is specified, substitution gives:

The positive solution for \(D\) decreases as \(R_{\mathrm{tot}}\) increases, because at any fixed positive \(D\) the right-hand side of the first equation increases with \(R_{\mathrm{tot}}\). Thus, under this fixed-total-antibody calculation, more target means less free antibody and a lower occupancy fraction, while the complex amount can rise. It is important not to confuse a change in total target with a change in occupancy at fixed free drug.

Turnover Can Matter Even at the Same Abundance

Two disease states can have the same drug-free target abundance but different synthesis and degradation rates. They will have the same \(R_0\) if the ratio \(k_{\mathrm{syn}}/k_{\mathrm{deg}}\) is equal, but they will not necessarily have the same response time. For a drug-free target whose synthesis changes to a constant value at time zero, with degradation rate \(k_{\mathrm{deg}}\), the solution is:

The exponential term shows that the approach rate depends on \(k_{\mathrm{deg}}\), not just on the new steady-state abundance. Consequently, a disease transition or treatment start can produce different time courses of target availability in states with the same eventual \(R_0\). This matters when antibody exposure or target occupancy is measured before target turnover has equilibrated.

Target-Mediated Loss Under Constant Input

A second reduced calculation illustrates how target abundance can influence free antibody exposure when complex internalization removes antibody. Assume constant input \(u\), first-order elimination of free antibody, a buffered accessible target pool, and the same rapid-binding relation. The steady-state antibody balance is:

For positive \(D\), the right-hand side increases with \(D\). At any fixed \(D\), it also increases with \(R_{\mathrm{tot}}\) if \(k_{\mathrm{int}}>0\). Therefore, to maintain the same input \(u\), a larger target pool implies a lower steady-state free \(D\) in this reduced model. This conclusion relies on complex internalization contributing to antibody loss; if complex dissociates without drug loss, the target-related contribution to net antibody clearance is different.

Diagnostics, Alternatives, and Limitations

A disease-dependent target model is only as credible as its representation of the biology and the data. Useful checks include confirming that the drug-free steady state \(k_{\mathrm{syn}}/k_{\mathrm{deg}}\) has the intended value and units, checking that all modeled states remain nonnegative, and verifying that drug and target mass balances behave as expected. Simulations should also examine target and complex time courses, not only antibody concentration. If a model predicts an implausible target accumulation, a negative state, or a large exposure shift unsupported by measured target or complex data, revisit the equations, units, initial conditions, and assumed disease effect.

The simplest alternative is to use a fixed target abundance. This can be reasonable when the disease state is stable and target turnover is not a question of interest, but it cannot represent a changing target pool. A constant synthesis multiplier is more mechanistic when disease is believed to alter production; a degradation-rate change is appropriate when disease is believed to alter target loss. A time-varying synthesis or degradation function can represent a changing disease state, but adds parameters that require evidence. More detailed models may also distinguish tissues or soluble and membrane target pools; they are warranted when those differences are important to the question and supported by data.

The reduced examples assume a buffered target pool and rapid binding. They are useful for direction-of-effect reasoning, but should not be treated as exact predictions when target depletion, slow binding, changing disease activity, or complex internalization substantially alters target abundance. The full differential-equation model is then needed, with parameters and initial conditions chosen for the intended biological setting. A further limitation is identifiability: antibody concentration data alone may not distinguish increased target synthesis from altered binding or complex internalization. Target and complex measurements, or informative prior biological knowledge, can help constrain those mechanisms.

• Pitfall: equating more target with proportionally lower antibody exposure. That conclusion does not follow from abundance alone. The effect depends on binding kinetics, input, elimination, and whether complex formation removes antibody.
• Pitfall: assuming occupancy must rise when complex rises. Occupancy is \(C/R_{\mathrm{tot}}\). A larger target pool can increase absolute complex while free antibody falls enough for fractional occupancy to decrease.
• Pitfall: representing altered turnover only as a new steady-state multiplier. Equal steady-state abundance does not imply equal transient responses; the degradation rate sets the response timescale.